Orphazyme: Competitor fails in NPC

Research Note

2018-11-07

16:39

Mallinckrodt has announced that their VTS-270 project, a competitor to Orphazyme's arimoclomol for the treatment of NPC, failed to show statistically significant efficacy in their Phase II/III trial. No details has been released around the data.

MS

Mathias Spinnars

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.